Logo image of XENE

XENON PHARMACEUTICALS INC (XENE) Stock Overview

NASDAQ:XENE - CA98420N1050 - Common Stock

38.64 USD
-0.19 (-0.49%)
Last: 9/4/2025, 8:00:02 PM
38.6 USD
-0.04 (-0.1%)
Pre-Market: 9/5/2025, 4:40:17 AM

XENE Key Statistics, Chart & Performance

Key Statistics
52 Week High46
52 Week Low26.74
Market Cap2.98B
Shares77.11M
Float75.53M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.55
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/amc
IPO10-17 2014-10-17
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


XENE short term performance overview.The bars show the price performance of XENE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15 20

XENE long term performance overview.The bars show the price performance of XENE in the last 1, 2 and 3 years. 1 year 2 years 3 years 2 4 6 8 10

The current stock price of XENE is 38.64 USD. In the past month the price increased by 12.75%. In the past year, price increased by 0.44%.

XENON PHARMACEUTICALS INC / XENE Daily stock chart

XENE Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.11 376.28B
AMGN AMGEN INC 12.84 150.79B
GILD GILEAD SCIENCES INC 14.57 139.93B
VRTX VERTEX PHARMACEUTICALS INC 23.43 101.77B
REGN REGENERON PHARMACEUTICALS 12.43 60.12B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.45B
ARGX ARGENX SE - ADR 79.14 44.90B
ONC BEONE MEDICINES LTD-ADR 6.42 37.89B
INSM INSMED INC N/A 30.13B
BNTX BIONTECH SE-ADR N/A 24.88B
NTRA NATERA INC N/A 22.86B
BIIB BIOGEN INC 8.74 20.52B

About XENE

Company Profile

XENE logo image Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 316 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

Company Info

XENON PHARMACEUTICALS INC

3650 Gilmore Way

Vancouver BRITISH COLUMBIA V5G 48W CA

CEO: Simon Pimstone

Employees: 316

XENE Company Website

XENE Investor Relations

Phone: 16044843300

XENON PHARMACEUTICALS INC / XENE FAQ

What is the stock price of XENON PHARMACEUTICALS INC today?

The current stock price of XENE is 38.64 USD. The price decreased by -0.49% in the last trading session.


What is the ticker symbol for XENON PHARMACEUTICALS INC stock?

The exchange symbol of XENON PHARMACEUTICALS INC is XENE and it is listed on the Nasdaq exchange.


On which exchange is XENE stock listed?

XENE stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for XENON PHARMACEUTICALS INC stock?

25 analysts have analysed XENE and the average price target is 55.35 USD. This implies a price increase of 43.25% is expected in the next year compared to the current price of 38.64. Check the XENON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is XENON PHARMACEUTICALS INC worth?

XENON PHARMACEUTICALS INC (XENE) has a market capitalization of 2.98B USD. This makes XENE a Mid Cap stock.


How many employees does XENON PHARMACEUTICALS INC have?

XENON PHARMACEUTICALS INC (XENE) currently has 316 employees.


What are the support and resistance levels for XENON PHARMACEUTICALS INC (XENE) stock?

XENON PHARMACEUTICALS INC (XENE) has a support level at 38.63 and a resistance level at 38.68. Check the full technical report for a detailed analysis of XENE support and resistance levels.


Is XENON PHARMACEUTICALS INC (XENE) expected to grow?

The Revenue of XENON PHARMACEUTICALS INC (XENE) is expected to grow by 2419.98% in the next year. Check the estimates tab for more information on the XENE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy XENON PHARMACEUTICALS INC (XENE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does XENON PHARMACEUTICALS INC (XENE) stock pay dividends?

XENE does not pay a dividend.


When does XENON PHARMACEUTICALS INC (XENE) report earnings?

XENON PHARMACEUTICALS INC (XENE) will report earnings on 2025-11-10, after the market close.


What is the Price/Earnings (PE) ratio of XENON PHARMACEUTICALS INC (XENE)?

XENON PHARMACEUTICALS INC (XENE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.55).


What is the Short Interest ratio of XENON PHARMACEUTICALS INC (XENE) stock?

The outstanding short interest for XENON PHARMACEUTICALS INC (XENE) is 9.13% of its float. Check the ownership tab for more information on the XENE short interest.


XENE Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to XENE. When comparing the yearly performance of all stocks, XENE turns out to be only a medium performer in the overall market: it outperformed 65.09% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

XENE Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to XENE. No worries on liquidiy or solvency for XENE as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

XENE Financial Highlights

Over the last trailing twelve months XENE reported a non-GAAP Earnings per Share(EPS) of -3.55. The EPS decreased by -29.56% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -41.26%
ROE -43.89%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-42.67%
Sales Q2Q%N/A
EPS 1Y (TTM)-29.56%
Revenue 1Y (TTM)N/A

XENE Forecast & Estimates

25 analysts have analysed XENE and the average price target is 55.35 USD. This implies a price increase of 43.25% is expected in the next year compared to the current price of 38.64.

For the next year, analysts expect an EPS growth of -42% and a revenue growth 2419.98% for XENE


Analysts
Analysts87.2
Price Target55.35 (43.25%)
EPS Next Y-42%
Revenue Next Year2419.98%

XENE Ownership

Ownership
Inst Owners103.44%
Ins Owners0.11%
Short Float %9.13%
Short Ratio5.92